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ABSTRACT
Background. Neoadjuvant chemoradiotherapy (NACRT)
for esophageal squamous cell carcinoma (ESCC) is bene-
ficial in the setting of a complete pathological response.
Rad51 expression affects both chemo- and radiosensitivity
in many cancers; however, its role in ESCC is unclear.
Methods. Rad51 expression was investigated by immuno-
histochemical staining with resected specimens in 89 ESCC
patients who underwent surgery without preoperative ther-
apy. The association with Rad51 and clinicopathological
factors was assessed. The expression of Rad51 was also
investigated in pretreatment biopsy specimens in 39 ESCC
patients who underwent surgery after NACRT and compared
with the pathological response to NACRT.
Results. Lymph node metastasis was more frequently
observed in Rad51-positive cases than negative cases (58.5
vs. 30.6 %, P = 0.0168) in patients treated with surgery
alone. Disease-specific survival was decreased in Rad51-
positive cases compared to Rad51-negative cases (5 year
survival: 79.6 vs. 59.3 %, P = 0.0324). In NACRT
patients, completed pathological responses were more
frequently observed in Rad51-negative cases than in
Rad51-positive cases (68.8 vs. 46.5 %, P = 0.0171).
Conclusions. Rad51 expression in ESCC was associated
with lymph node metastasis and poor survival. Addition-
ally, Rad51 expression in pretreatment biopsy specimens
was a predictive factor for the response to NACRT.
Esophageal cancer, unlike other gastrointestinal malig-
nancies, is extremely difficult to control with surgery alone.1
Neoadjuvant chemoradiotherapy (NACRT), frequently with
cisplatin, is an important treatment strategy for advanced
esophageal squamous cell carcinoma (ESCC); however, the
clinical usefulness of NACRT for potentially resectable
esophageal cancer remains controversial. In multiple meta-
analyses, neoadjuvant treatment has been demonstrated to be
superior to primary surgery in terms of local tumor control
and disease-free survival.2–4 Other reports, however, have
not demonstrated NACRT plus surgery to be superior to
surgery alone.5–7 NACRT for esophageal cancer may also
increase the risk of perioperative complications.8,9 There-
fore, identification of molecular markers that predict the
response to NACRT could potentially reduce perioperative
complications by improving patient selection.
One predictive factor for chemoradiotherapy response in
a variety of human cancers is Rad51.10,11 Rad51 is a key
factor in homologous recombination.12 Overexpression of
Rad51 decreases radiation sensitivity and confers resis-
tance to DNA cross-linking agents such as cisplatin.13,14
We therefore hypothesized that Rad51 expression would
predict the response to NACRT in ESCC.
The aims of this study were to evaluate the significance
of Rad51 in ESCC and to correlate Rad51 expression in the
pretreatment biopsy ESCC specimens with NACRT
response.
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MATERIALS AND METHODS
Patients
Between July 1997 and March 2006, 89 patients (pT1–3,
pN0–1, M0) with ESCC underwent esophagectomy with-
out neoadjuvant therapy at the Department of Surgery and
Science, Kyushu University Hospital, Fukuoka, Japan. The
78 male patients and 11 female patients ranged in age from
38 to 90 years (mean 63.3 years). Using the resected
specimens from these patients, we evaluated the signifi-
cance of the overexpression of Rad51 in ESCC.
For the NACRT group, patients were treated between
2003 and 2008. Thirty-nine patients (cT1–4, N0–1, M0) with
ESCC underwent NACRT followed by esophagectomy: 22
patients at the Department of Surgery and Science, Kyushu
University Hospital, and 17 patients at National Hospital
Organization Kyushu Cancer Center, Fukuoka, Japan. For
NACRT, 30–42 Gy of radiation was administered preoper-
atively to the primary tumor and metastatic lymph nodes.
The chemotherapy regimen consisted of low-dose cisplatin
and 5-fluorouracil (5-FU) (cisplatin: 5 mg/m2/day, 5-FU:
250 mg/m2/day, administered on weekdays, repeated every
3–4 weeks). Using pretreatment biopsy specimens in these
patients, we compared the effectiveness of NACRT with the
expression of Rad51.
Immunohistochemistry
All surgically resected tumor specimens and biopsy
specimens were fixed with 10 % formalin and embedded in
paraffin. Four-micrometer sections were deparaffinized
with xylene and rehydrated in a series of ethanols. Heat-
induced epitope retrieval was performed in 0.1 M NaOH-
citrate buffer (pH 7.0) for Rad51 immunostaining, and the
samples were heated in an autoclave at 121 C for 15 min.
Endogenous peroxidase was blocked at room temperature
using 3 % hydrogen peroxide in methanol for 30 min.
After blocking with normal goat serum, slides were incu-
bated with mouse monoclonal antibody against Rad51
(MS-988-P, NeoMarkers, Fremont, CA) using a 1:100
dilution of primary antibody at 4 C overnight. After
washing, the sections were treated for 60 min at room
temperature with goat–anti-mouse immunoglobulin.
Staining for Rad51 was completed using the streptavidin–
biotin–peroxidase complex method with diaminobenzidine
as a chromogen, and the slides were counterstained with
hematoxylin. Positive staining was defined as a minimum
of 10 % of the cancer cell nuclei showing positive nuclear
staining.15 The tumors were staged according to the
International Union Against Cancer’s tumor, node, metas-
tasis (TNM) classification.16 A pathological complete
response (pCR) was defined as no evidence of viable
cancer cells in the primary regions; a pathological nonre-
sponse was defined as viable cancer cells still observed.
Assessment of Rad51 Staining in ESCC
Immunohistochemical staining was assessed for 89 sam-
ples from patients without preoperative therapy and 39
samples from patients who had undergone NACRT. Staining
was scored under a light microscope by a pathologist
(Nakashima Y) who was unaware of the clinical, patholog-
ical, and follow-up data. The concept of positive-cell index
(PCI), indicating the proportion of positively stained tumor
cells, was adopted for the analyses in this study. Rad51-
positive staining was defined by identifying the optimal
cutoff point. Qiao et al.15 have previously reported the
optimal threshold required to separate prognostically. For
this procedure, a PCI of 10 % was identified as the optimal
cutoff. Cases whose immunohistochemistry (IHC) scores
were less than 10 % were called ‘‘low-level expressers,’’
whereas those with IHC scores greater than 10 % were called
‘‘high-level expressers.’’ High-level expressers were defined
as Rad51-positive staining cases, and low-level expressers
were defined as negative staining cases.
In order to evaluate the heterogeneity of staining, we
evaluated the area of Rad51 staining by dividing the tumor
nest into three equal parts: the shallow level, the middle
level, and the deep level of the invasive cancer.17 Homoge-
nous staining was defined by identical staining patterns in all
three parts of the tumor. If the staining pattern was homog-
enous, the Rad51 status in the biopsy specimen was
considered to reflect the results in the surgical specimen.
Statistical Analysis
The differences in distribution frequencies among the
groups were evaluated using Fisher’s exact test or an
unpaired t-test. The survival curves were plotted according
to the Kaplan–Meier method and any differences were
analyzed using the log-rank test. A multivariate analysis
with Cox proportional hazards model was adopted to
clarify the independent prognostic factors. Differences
were considered to be significant if the P value was less
than 0.05.
RESULTS
Rad51 Expression in the Resected Specimens
and Clinicopathological Factors in the Patients Who
Underwent Surgery Without Preoperative Therapy
Positive staining of Rad51 was observed in 53 (59.6 %)
of 89 cases (Fig. 1). The patterns of Rad51 staining were
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homogenous in almost all specimens (Fig. 2). Additionally,
46 of 53 (86.7 %) cases without NACRT presented diffuse
staining patterns from the shallow to deep levels of the
tumor nest, with the expression pattern of Rad51 appearing
homogenous. In the seven cases exhibiting heterogeneous
staining patterns, there was no expression of Rad51 in the
shallow level, while positive expression was observed in
the middle and deep levels of the tumor.
There was a significant association between Rad51
expression and lymph node metastasis with node positive
cases numbering 11 (30.6 %) and 31 (58.5 %) in the Rad51
negative and positive groups, respectively (Table 1, P =
0.0168). There were no significant associations between
Rad51 expression and age, gender, or tumor location. There
was no significant association between Rad51 expression
and overall survival (Fig. 3; 5-year survival rates: 57.0
versus 65.4 %, for positive and negative, respectively;
P = 0.1768). Rad51-positive cases had significantly poorer
disease-specific survival compared to Rad51-negative cases
(Fig. 3; 5-year disease-specific survival rates: 59.3 versus
79.6 % for positive and negative, respectively; P = 0.0324).
In Rad51-negative cases, recurrence was less frequent than
in Rad51-positive cases (Table 1; 9 of 36 cases versus 27 of
53 cases; P = 0.0171). In multivariate analysis, Rad51 was
not an independent prognostic factor (Table 2, P = 0.5287),
while lymph node metastasis was an independent prognostic
factor (P = 0.0051).
Rad51 Expression in the Biopsy Specimens
and Clinicopathological Factors in the Patients Who
Underwent Surgery after NACRT
Negative staining of Rad51 was observed in 12 (30.8 %)
of 39 cases, while 27 cases were positive (69.2 %, Fig. 4).
With respect to the efficacy of NACRT, seven of 39 cases
(17.9 %) were histologically pCR. There were no signifi-
cant associations between demographic and clinical
factors, depth of invasion, lymph node metastasis, or TNM
clinical stage (Table 3). Rad51 expression significantly
predicted a response to NACRT; five (41.7 %) of 12 Rad51
negative cases were classified as pCR, while seven cases
(58.3 %) were non-pCR patients. Twenty-five of 27 Rad51
positive cases (92.6 %) were non-pCR to NACRT with
only two Rad51 positive cases (7.4 %) being classified as
pCR (Table 4, P = 0.0197).
DISCUSSION
Overexpression of Rad51 has been observed in several
cancers and may be involved in either the initiation or the
progression of tumorigenesis.18,19 In non-small cell lung
cancer (NSCLC), overexpression of Rad51 is related to
decreased survival and increased tumor cell survival.15
Overexpression of Rad51 has been reported to correlate
FIG. 1 Immunohistochemistry for the detection of Rad51 in the
resected specimens by esophagectomy without preoperative therapy
(original magnification, 9200). Immunohistochemistry for Rad51 in
ESCC resected specimens without preoperative therapy. Positive
staining of Rad51 was present in 53 (59.6 %) cases and negative
staining in 36 (40.4 %)
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P 7
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FIG. 2 Rad51 staining patterns in surgical specimens. In 46 (86.7 %)
cases of Rad51-positive staining in surgical specimens, a homogenous
staining pattern was observed. In the seven cases with heterogeneous
staining patterns, there was no expression of Rad51 in the shallow
level, while positive expression was observed in the middle and deep
levels of the tumor
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with histological grading of sporadic invasive ductal breast
cancer, and is more frequently observed in advanced
prostate cancer.18,19 These results suggest a relationship
between Rad51 overexpression and more aggressive tumor
behavior.
In ESCC, the significance of Rad51 overexpression is
still unclear. In this study, high expression of Rad51 was
associated with lymph node metastases in cases of esoph-
ageal cancer in which the patients had not undergone
NACRT. However, the mechanism through which Rad51
expression affects the migratory ability of cancer cells has
not been elucidated. Using canine adenocarcinoma meta-
static models, it was demonstrated that Rad51 mRNA
overexpression could be observed in metastatic lymph
nodes.20 However, the details of the metastatic mechanisms
mediating these effects are still unclear. In breast cancer,
pancreatic cancer, soft tissue sarcoma, and non–small cell
lung cancer, Rad51 overexpression was associated with
poor prognoses, suggesting that Rad51 overexpression may
enhance genetic instability and maintain DNA damage at a
tolerable level to permit cell survival.15,18,21,22 The rela-
tionship between overexpression of double-stranded break
(DSB) repair genes and the ability of tumor cells to
undergo migration has not yet been elucidated. XRCC3, a
DSB repair gene, was reported to be associated with
increased tumor cell migration in breast cancer cells.23
Considering our results, which demonstrated that ESCC
specimens with Rad51 overexpression often exhibited
lymph node metastasis, further studies are needed to
investigate the role of Rad51 using ESCC cell lines. On the
basis of data from a tissue microarray, Li et al.24 reported
that Rad51 was an independent prognostic factor in ESCC.
In this study, Rad51 expression was investigated by con-
ventional IHC using surgical resection and biopsy
specimens. It is possible to investigate the entire cancer
area using surgical and biopsy specimens by IHC; how-
ever, histological observation of the tumor nest is limited in
tissue microarray analysis. Thus, differences in the evalu-
ation methods for Rad51 expression may explain the
inconsistencies between our study and previous studies.
In our study, some population bias was observed
between the groups with and without NACRT; the NACRT
group included more advanced cases of ESCC than the
group without NACRT. Because there was a discrepancy in
the association between lymph node metastasis and Rad51
expression in the groups with and without NACRT, we also
analyzed Rad51 expression and clinicopathological factors,
matching the staging of subjects. When limited to Stage I/II
cases or Stage III cases, there were no significant rela-
tionships between lymph node metastasis and Rad51
expression, both in patients with and without NACRT,
suggesting that the population bias resulted in variations in
the association between lymph node metastasis and Rad51
expression (data not shown). Additionally, differences in
staging methods, i.e. that patients’ backgrounds were based
on pathological staging in the without NACRT group but
on clinical staging in the with NACRT group, could
explain the discrepancy in the association between lymph
node metastasis and Rad51 expression in the three groups.
Our data indicated that Rad51 expression status in
biopsy specimens could be a predictive factor for treatment
efficacy of NACRT in ESCC. Because the Rad51 staining
pattern was homogenous in the majority of cases, the
expression pattern of biopsy specimens was considered to
reflect the Rad51 expression status in the whole tumor nest.
In assessment of the HER2 status of gastric cancer
TABLE 1 Rad51 expression in the resected specimen and clinico-
pathological factors in patients who underwent surgery without
preoperative therapy
Factor Rad51
negative
Rad51
positive
P value
(n = 36) (n = 53)
Age (year) 62.3 ± 10.1 64.1 ± 9.9 0.5193
Sex 0.5144
Male 33 (91.7 %) 45 (84.9 %)
Female 3 (8.3 %) 8 (15.1 %)
Differentiation of ESCC 0.0999
Well 8 (22.2 %) 15 (28.3 %)
Moderate 24 (66.7 %) 24 (45.3 %)
Poor 4 (11.1 %) 14 (26.4 %)
Location 0.1083
Upper 3 (8.4 %) 8 (15.1 %)
Middle 21 (58.3 %) 19 (35.9 %)
Lower 12 (33.3 %) 26 (49.1 %)
Depth of invasion 0.1246
pT 1, 2 25 (69.4 %) 27 (50.9 %)
pT 3 11 (30.6 %) 26 (49.1 %)
Lymph node metastasis 0.0168
pN 0 25 (69.4 %) 22 (41.5 %)
pN 1 11 (30.6 %) 31 (58.5 %)
Lymphatic involvement 0.2794
Negative 22 (61.1 %) 25 (47.2 %)
Positive 14 (38.9 %) 28 (52.8 %)
Vascular involvement 1.0000
Negative 25 (69.4 %) 36 (67.9 %)
Positive 11 (30.6 %) 17 (32.1 %)
pStage 0.0905
I, II 30 (83.3 %) 35 (66.0 %)
III 6 (16.7 %) 18 (34.0 %)
Recurrence 0.0171
Negative 27 (75.0 %) 26 (49.1 %)
Positive 9 (25.0 %) 27 (50.9 %)
ESCC esophageal squamous cell carcinoma
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biopsies, the concordance rate of diagnosis between biopsy
and surgical specimens was reported to be over 70 %.25,26
In this study, the concordance of Rad51-positive staining
was 86.7 %, suggesting that Rad51 IHC results in biopsy
specimens are useful as a predictive tool of Rad51-positive
staining in surgical specimens, similar to the usefulness of
HER2 status in biopsies of gastric cancer specimens.
Our data suggested that Rad51 is a useful predictive tool
for NACRT in ESCC. However, Rad51 expression incom-
pletely predicted the efficacy of NACRT, implying that the
TABLE 2 Multivariate analysis of Rad51 expression in the without NACRT
Factor Object Control Odds ratio 95 % confidence interval P value
Depth of invasion T3/T4 T1/T2 0.92 0.77–2.12 0.3376
Lymph node metastasis Positive Negative 7.85 1.27–3.74 0.0051
Distant metastasis Positive Negative 0.05 0.19–4.16 0.8251
Recurrence Positive Negative 3.39 0.96–2.88 0.0654
Rad51 Positive Negative 0.40 0.73–1.89 0.5287
NACRT neoadjuvant chemoradiotherapy
Rad51 negative (n=36)
Rad51 positive (n=53)
Rad51 negative (n=36)
Rad51 positive (n=53)
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FIG. 3 Survival for patients
without preoperative
chemoradiotherapy.
Comparison of the 5-year OS
rate and DSS rate between
Rad51 positive and negative
staining groups in ESCC
without preoperative therapy.
The difference in DSS was
statistically significant
(P = 0.0324)
FIG. 4 Immunohistochemistry
for Rad51 in the biopsy
specimens before preoperative
therapy. Positive staining was
present in 27 (69.2 %) cases,
and 12 (30.8 %) cases were
negative
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pathway is multifactorial. Thus, further studies are required
in order to elucidate other mechanisms and markers that
would allow us to predict the efficacy of NACRT.
DNA double strand breaks (DSBs), if unrepaired, are
lethal to the tumor cell. Radiation and cisplatin trigger
apoptosis in tumor cells by creating genetic instability
through a DSBs mechanism.27 Rad51 plays an important
role in the repair of DSBs through homologous recombi-
nation, thereby decreasing sensitivity to radiation and
cisplatin. Radiation and CDDP inhibits cellular growth by
inducing DNA DSBs.28–30 Cells can use DNA repair
machinery to respond to the DNA damage. The levels of
DNA repair proteins correlate with resistance to radiation
and anticancer drugs in human cancer cell lines.12,31 Two
pathways, homologous recombination and nonhomologous
end joining, are used to repair DNA DSBs, and Rad51 is
involved in the former process, homologous recombina-
tion. Recent evidence suggests that homologous
recombination is involved in the repair of DNA DSBs
generated by radiation and CDDP.14,32,33 Cancer cells may
become resistant to radiation and CDDP by increasing the
activity of homologous recombination repair machinery.34
On the other hand, 5-FU, an antimetabolic drug, exerts its
antitumor effects through suppression of both DNA and
RNA synthesis, pathways separate from CDDP or radia-
tion. Because there are few studies of the direct
relationship between DSB repair and 5-FU, further inves-
tigations with ESCC cells are required to elucidate the role
of Rad51 in 5-FU sensitivity.35
In recent studies, down-regulation of Rad51 has been
demonstrated to increase therapeutic sensitivities. In
NSCLC, Tsai et al. reported that down-regulation of Rad51
using specific Rad51 small interfering RNA significantly
increased cytotoxicity.36 Chan et al. 37 reported that down-
regulation of Rad51 decreased homologous recombination,
and increased sensitivity to the DNA cross-linking agents
mitomycin C and cisplatin. Down-regulation of homolo-
gous recombination could result in low-fidelity DNA repair
and have significant implications for response to therapy
and genetic instability. Cancer cells may become resistant
to cisplatin by increasing the activity of homologous
recombination repair via Rad51 over expression. Down-
regulation of Rad51 in ESCC may represent a novel ther-
apeutic strategy to increase sensitivity for radiation and
cisplatin chemotherapy.
In ESCC, radiation and cisplatin are the mainstays of
treatment.38–42 NACRT with cisplatin results in significant
down staging and induces pCR.43,44 A pCR to NACRT is
critical for improving the survival of patients with ESCC.45
NACRT may, however, increase the incidence of postoper-
ative complications.46 Thus, patient selection should identify
those patients unlikely to benefit from NACRT. Although
several other predictive factors have been reported, clear
molecular prognostic factors are still needed to reduce the
frequency of perioperative complications.47–49 On the basis
of our results, Rad51 has great potential and warrants further
investigation.
TABLE 3 Rad51 expression and clinical factors in patients with
NACRT
Factor Rad51
negative
Rad51
positive
P value
(n = 12 %) (n = 27 %)
Age (year) 58.8 ± 12.3 62.5 ± 7.9 0.3071
Sex 0.6536
Male 9 (75.0 %) 23 (85.2 %)
Female 3 (25.0 %) 4 (14.8 %)
Differentiation of ESCC 0.6641
Well 2 (16.7 %) 8 (29.6 %)
Moderate 8 (66.6 %) 16 (59.3 %)
Poor 2 (16.7 %) 3 (11.1 %)
Location 0.1850
Upper 3 (25.0 %) 10 (37.0 %)
Middle 4 (33.3 %) 13 (48.2 %)
Lower 5 (41.7 %) 4 (14.8 %)
Depth of invasion 1.0000
cT 1, 2 2 (16.7 %) 4 (14.8 %)
cT 3 10 (83.3 %) 23 (84.6 %)
Lymph node metastasis 0.2694
cN 0 2 (16.7 %) 11 (40.7 %)
cN 1 10 (83.3 %) 16 (59.3 %)
cStage 0.6450
I, II 1 (8.3 %) 5 (18.5 %)
III 11 (91.7 %) 22 (81.5 %)
NACRT neoadjuvant chemoradiotherapy, ESCC esophageal squamous
cell carcinoma
TABLE 4 Relationship of Rad51 expression and the responses of NACRT
Efficacy of NACRT Expression of Rad51 P value
Negative (n = 12) Positive (n = 27)
Non-pCR 7 (58.3 %) 25 (92.6 %) 0.0197
pCR 5 (41.7 %) 2 (7.4 %)
NACRT neoadjuvant chemoradiotherapy, pCR pathological complete response
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Considering our results, NACRT using a cisplatin/5-FU
protocol is likely to fail when Rad51 overexpression is
observed on a biopsy specimen. Use of NACRT for these
patients may unnecessarily increase the rate of periopera-
tive complications as there is no nonsurgical alternative to
esophagectomy. In the current study, docetaxel, cisplatin
and fluorouracil combination chemotherapy has been
demonstrated to have activity in advanced and recurrent
ESCC.50 Cetuximab may also have activity in ESCC.51,52
Rad51 targeted therapies may represent another novel
therapeutic strategy.
In conclusion, Rad51 expression may predict NACRT
response in ESCC. Rad51 expression may serve as a means
by which to select patients for NACRT, thereby minimiz-
ing perioperative complications.
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